HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target
Benzinga Newsdesk 16 hours ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.
